VC Atlas takes on biotech veteran Kevin Bitterman

Bitterman has worked at Polaris and been involved in founding a number of high spec biotechs.

Atlas Venture has made biotech veteran Kevin Bitterman a new partner, joining the firm’s team from Polaris.

Bitterman brings a wealth of experience to the role, having been the founding CEO of CRISPR biotech Editas Medicine, Morphic Therapeutic and Visterra, as well as co-founder of Genocea Biosciences.

“I couldn’t be more thrilled to join Atlas at such an exciting time for the firm,” said Bitterman. “Atlas has a deep commitment to transforming medicine through groundbreaking science and a rich history of partnering with entrepreneurs at the earliest stages of company inception. I’m looking forward to contributing as the team builds the next generation of great biotech companies.”

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

“Kevin is an exceptional venture investor who brings proven company creation skills and deep scientific expertise to Atlas,” added David Grayzel, an Atlas partner. “We have known Kevin for years in the Boston biotech ecosystem and are delighted to welcome him to the team.”

Atlas has had a busy year, helping with a series of funding rounds for biotechs, and late last year, in a first for the life science venture capital world, teamed up with Third Rock in a $48.5 million Series A to create and launch Magenta Therapeutics—a new biotech that aims to reset and refresh the immune system.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.